SHANGHAI, June 26 (Reuters) - A cancer cell therapy from

CSPC Pharmaceutical Group ( CHJTF ) that uses synthetic

messenger RNA (mRNA) technology has received regulatory

clearance in China for human clinical trial, the Chinese

drugmaker said late on Tuesday.

CSPC and several other Chinese drugmakers have researched

synthetic mRNA to develop vaccines during the COVID-19 pandemic

and have since continued testing new uses for the technology,

including in cancer treatments.

"The clinical trial approval obtained for the product marks

the first significant achievement of the Group in the field of

cell therapy," CSPC said in a stock exchange filing, referring

to the approval by the China National Medical Products

Administration.

CSPC's therapy SYS6020 can target and kill myeloma cells

with "minimal side effects", it said. It also has potential to

be used for the treatment of autoimmune diseases including

systemic lupus erythematosus and myasthenia gravis, it added.

A spokesperson for CSPC did not immediately respond to

Reuters questions about the technology used in SYS6020, which it

described as the "world's first mRNA-LNP-based cell therapy

product approved for clinical trials".